Graft-versus-host disease (GVHD) of the skin is a condition where donated immune cells from a stem cell transplant attack the recipient’s skin tissue. It is the most common way GVHD shows up in the body and is often the very first sign that the disease is developing. Skin GVHD can appear as an acute reaction in the weeks after transplant or develop into a chronic condition that persists for months or years, each with distinct symptoms and challenges.
Why the Skin Gets Attacked
During an allogeneic stem cell transplant (where the donor is another person), the donated cells rebuild a new immune system inside your body. But the donor’s immune cells, specifically a type called T cells, can recognize your tissues as foreign. Your own cells present proteins on their surface that look different enough from the donor’s to trigger an immune response. The donor T cells activate, multiply, and begin attacking your healthy tissue.
The skin is a frequent target partly because it contains a dense population of immune-signaling cells. Research has also shown that skin stem cells themselves can be injured during GVHD, which disrupts the skin’s ability to repair and maintain itself normally. This helps explain why chronic skin GVHD can cause lasting changes to skin texture and appearance rather than just temporary inflammation.
How Acute Skin GVHD Looks and Feels
Acute skin GVHD typically appears after the transplanted cells have engrafted, usually within the first few weeks to about 100 days post-transplant. A rare, more severe “hyperacute” form can show up within the first two weeks. The earliest sign is often redness around hair follicles, which can be subtle and easy to miss.
The classic presentation is a red, bumpy rash that starts on the face, ears, palms, and soles of the feet. From there, it frequently spreads to the trunk. In mild cases, the rash covers less than 25% of the body’s surface. In moderate cases, it extends to 25 to 50%. Severe cases cover more than half the body, and the most extreme form involves widespread redness with blistering and peeling skin that can resemble a severe drug reaction.
Chronic Skin GVHD: A Different Disease
Chronic skin GVHD develops later, sometimes overlapping with acute disease and sometimes appearing months or even years after transplant. It looks and behaves quite differently from the acute form and generally falls into two broad patterns.
The first pattern involves surface-level skin changes: patches that look scaly, dry, or similar to lichen planus (flat-topped, purplish bumps). The skin may itch persistently, and color changes, either darker or lighter patches, are common.
The second, more serious pattern is sclerotic (hardening) disease. Here, inflammation drives fibrosis deep into the skin and the tissue beneath it. The skin becomes thick, tight, and bound down, sometimes resembling localized patches of hardened skin or, in widespread cases, a condition similar to systemic sclerosis. Patients with this form report significantly more skin thickening, color changes, skin sores, itching, and joint stiffness compared to those without sclerotic involvement. When the torso is affected, the tightened skin can even restrict chest wall expansion and make breathing feel harder.
Who Is at Higher Risk
Not everyone who receives a stem cell transplant develops skin GVHD. Several factors increase the likelihood:
- Donor mismatch: The greater the difference in tissue type (HLA markers) between donor and recipient, the higher the risk.
- Unrelated donors: Transplants from unrelated donors carry more risk than those from matched siblings.
- Donor characteristics: Older donors and female donors who have had multiple pregnancies are associated with higher rates.
- Recipient age: Older recipients face greater risk.
- Conditioning regimen: Treatments that include total body irradiation before transplant increase the chance of acute skin GVHD.
- Transplant history: Receiving more than one stem cell transplant raises risk further.
Interestingly, patients who receive reduced-intensity conditioning regimens tend to develop acute skin GVHD later and often need more treatment to bring it under control, likely because their immune systems shift more gradually after transplant.
How It Is Diagnosed
Doctors often suspect skin GVHD based on its appearance and timing relative to the transplant. A skin biopsy can confirm the diagnosis. Under the microscope, the hallmark findings include damage to cells at the base of the outer skin layer (vacuolar degeneration), individual dying skin cells scattered through the tissue, sponge-like swelling between cells, and immune cells infiltrating from the deeper skin into the lower layers of the epidermis. These features together create a recognizable pattern, though the biopsy findings can sometimes overlap with drug reactions or viral rashes, which is why clinical context matters.
Treatment for Skin GVHD
The standard first-line treatment for acute GVHD is systemic corticosteroids, which suppress the overactive donor immune cells. Mild cases limited to the skin may respond to topical steroid creams or ointments alone. For chronic skin GVHD affecting the surface layers, a common approach is applying a prescription-strength steroid ointment after soaking the skin in plain warm water for about 20 minutes, a technique that improves absorption. Many patients prefer using a cream formulation during the day under clothing and switching to an ointment at night for better coverage.
When steroids are not enough or when the disease becomes chronic and resistant, newer targeted medications are available. In the past decade, four drugs have received FDA approval specifically for chronic GVHD: ibrutinib, ruxolitinib, belumosudil, and axatilimab. These work through different pathways to calm the immune attack and have given patients options that did not exist a generation ago.
Light therapy (phototherapy) is another tool used for skin-predominant disease, though patients taking certain oral medications for phototherapy sessions need to wear protective eyewear for 24 hours afterward to prevent eye damage.
Complications of Skin Involvement
Skin GVHD is not just a surface problem. When chronic sclerotic disease extends into the fascia (the connective tissue wrapping around muscles), it can cause fasciitis that directly restricts joint movement. Over time, fibrotic tissue tightens around joints, leading to contractures where a joint becomes permanently difficult to bend or straighten. Once contractures develop, the outlook worsens, which is why early physical therapy, including stretching and myofascial massage, is important to maintain range of motion before tightening becomes irreversible.
Damaged skin also loses some of its ability to act as a barrier against infection. In severe cases with blistering or open sores, bacterial infections become a real concern. Sepsis has been documented as a cause of death in patients with musculoskeletal and skin GVHD, underscoring how seriously skin breakdown needs to be managed.
Daily Skin Care Matters
Beyond prescription treatments, consistent skin care plays a meaningful role in managing symptoms and protecting fragile skin. Keeping the skin well moisturized helps maintain the barrier function that GVHD disrupts. Sun protection is also important, since affected skin can be more sensitive to UV damage and because some treatments increase photosensitivity. Gentle cleansing, avoiding harsh soaps, and applying thick emollients regularly are simple steps that complement medical treatment and can reduce discomfort from dryness and itching.